Recurrent Malignant Glioma – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Malignant gliomas consist of glioblastomas, anaplastic oligodendrogliomas, anaplastic astrocytomas, and some less common tumors such as anaplastic ependymomas and anaplastic gangliogliomas. Malignant gliomas have high morbidity and mortality. With optimal treatment, the median survival for glioblastomas is only 12–15 months, and 2–5 years for anaplastic gliomas. Recent advances in our understanding of the molecular pathogenesis of malignant gliomas have resulted in the development of targeted chemotherapeutic agents. Furthermore, advances in diagnostic imaging have enabled the early detection and treatment of malignant gliomas. Meaningful palliation is possible for selected patients with recurrent malignant glioma (glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, or anaplastic mixed oligoastrocytoma) using aggressive treatment. Although long-term disease-free survival occurs in fewer than 10% of patients, most who achieve such survival have been treated for multiple recurrences.

 

The estimated number of new cases of primary malignant brain and central nervous system cancers is 3.8 per 100,000 in males and 3.1 per 100,000 in females.

The annual incidence of primary malignant gliomas in the US is approximately five cases per 100,000 people. Every year, about 22,500 new malignant prior brain tumor cases are diagnosed in adults in the US, out of which 70% are malignant gliomas.

 

The competitive landscape of Recurrent Malignant Glioma includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Recurrent Malignant Glioma across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent Malignant Glioma Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Recurrent Malignant Glioma – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. no    Asset   Company         Stage

1          WP1066           Moleculin Biotech          Phase 1

2          OKN-007          Oblato, Inc.       Phase 2

3          CTO     Tactical Therapeutics, Inc.         Phase 1

4          Cerebraca wafer           Everfront Biotech Co., Ltd.         Phase 2

5          LY2157299       Eli Lilly and Company    Phase 1

6          VAL-083           DelMar Pharmaceuticals, Inc.    Phase 2

7          Icapamespib     Samus Therapeutics, Inc.          Phase 1

8          Lenvatinib         Eisai Inc.          Phase 2

9          ANG1005          Angiochem Inc  Phase 2

10        DNX-2401         DNAtrix, Inc.     Phase 1

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more